Fanconi anaemia: Genetics, molecular biology, and cancer - implications for clinical management in children and adults

Clinical Genetics

Volumn 88, Issue 1, 2015, Pages 13-24

  Schneider, M ^a,b   Chandler, K ^a,b   Tischkowitz, M ^c   Meyer, S ^a,b,d,e  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^e CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Bone marrow failure; Cancer; Congenital abnormalities; Fanconi anaemia

Indexed keywords

BONE MARROW DEPRESSION; CARCINOGENESIS; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CONGENITAL DISORDER; CONGENITAL MALFORMATION; DUODENUM ATRESIA; FANCONI ANEMIA; FERTILITY; FOREARM; GENE THERAPY; GENETIC ANALYSIS; HAND; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEREDITY; HUMAN; HYDROCEPHALUS; HYPOPHYSIS DISEASE; KIDNEY DISEASE; MALE INFERTILITY; MENTAL DEFICIENCY; MICROPHTHALMIA; MOLECULAR BIOLOGY; MOLECULAR GENETICS; NEOPLASM; PRIORITY JOURNAL; REVIEW; SHORT STATURE; SKELETON MALFORMATION; SKIN PIGMENTATION; SQUAMOUS CELL CARCINOMA; SUBFERTILITY; URINARY TRACT DISEASE; ADULT; CHILD; COMPLICATION; CONGENITAL ABNORMALITIES; DISEASE MANAGEMENT; FEMALE; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; MALE; NEOPLASMS; PHENOTYPE;

ADULT; CHILD; CONGENITAL ABNORMALITIES; DISEASE MANAGEMENT; FANCONI ANEMIA; FEMALE; GENE-ENVIRONMENT INTERACTION; HUMANS; MALE; NEOPLASMS; PHENOTYPE;

EID: 84930389246     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12517     Document Type: Review

References (103)

1. Fanconi G. Familiäre, infantile, perniziosaartige Anämie (perniziöses Blutbild und Konstitution). Jb Kinderheilk 1927: 117: 257.
2. Naegeli O. Blutkrankheiten und Blutdiagnostik. In: Lehrbuch der Klinischen Hämatologie. Berlin: Julius Springer, 1931.
3. Grafe E. Book notices: Blutkrankheiten und Blutdiagnostik: Lehrbuch der klinischen Hämatologie. JAMA 1931: 97: 344.
4. Auerbach AD. Fanconi anemia and its diagnosis. Mutat Res 2009: 668: 4-10.
5. Kutler DI, Singh B, Satagopan J et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 2003: 101: 1249-1256.
6. Neveling K, Endt D, Hoehn H, Schindler D. Genotype-phenotype correlations in Fanconi anemia. Mutat Res 2009: 668: 73-91.
7. Huck K, Hanenberg H, Gudowius S et al. Delayed diagnosis and complications of Fanconi anaemia at advanced age - a paradigm. Br J Haematol 2006: 133: 188-197.
8. Faivre L, Portnoi MF, Pals G et al. Should chromosome breakage studies be performed in patients with VACTERL association? Am J Med Genet A 2005: 137: 55-58.
9. Sasaki MS, Tonomura A. A high susceptibility of Fanconi's anemia to chromosome breakage by DNA cross-linking agents. Cancer Res 1973: 33: 1829-1836.
10. Oostra AB, Nieuwint AW, Joenje H, de Winter JP. Diagnosis of fanconi anemia: chromosomal breakage analysis. Anemia 2012: 2012: 238731.
11. Shimamura A, Montes de Oca R, Svenson JL et al. A novel diagnostic screen for defects in the Fanconi anemia pathway. Blood 2002: 100: 4649-4654.
12. Lo Ten Foe JR, Kwee ML, Rooimans MA et al. Somatic mosaicism in Fanconi anemia: molecular basis and clinical significance. Eur J Hum Genet 1997: 5: 137-148.
13. Howlett NG, Taniguchi T, Olson S et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002: 297: 606-609.
14. Meyer S, Tischkowitz M, Chandler K, Gillespie A, Birch JM, Evans DG. Fanconi anaemia, BRCA2 mutations and childhood cancer: a developmental perspective from clinical and epidemiological observations with implications for genetic counselling. J Med Genet 2014: 51: 71-75.
15. Reid S, Schindler D, Hanenberg H et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 2007: 39: 162-164.
16. Xia B, Dorsman JC, Ameziane N et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 2007: 39: 159-161.
17. Tischkowitz M, Xia B. PALB2/FANCN: recombining cancer and Fanconi anemia. Cancer Res 2010: 70: 7353-7359.
18. Levitus M, Waisfisz Q, Godthelp BC et al. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group. Nat Genet 2005: 37: 934-935.
19. Vaz F, Hanenberg H, Schuster B et al. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet 2010: 42: 406-409.
20. Shamseldin HE, Elfaki M, Alkuraya FS. Exome sequencing reveals a novel Fanconi group defined by XRCC2 mutation. J Med Genet 2012: 49: 184-186.
21. Park DJ, Lesueur F, Nguyen-Dumont T et al. Rare mutations in XRCC2 increase the risk of breast cancer. Am J Hum Genet 2012: 90: 734-739.
22. Meindl A, Hellebrand H, Wiek C et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010: 42: 410-414.
23. Domchek SM, Tang J, Stopfer J et al. Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. Cancer Discov 2013: 3: 399-405.
24. Bogliolo M, Schuster B, Stoepker C et al. Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia. Am J Hum Genet 2013: 92: 800-806.
25. Tischkowitz M, Easton DF, Ball J, Hodgson SV, Mathew CG. Cancer incidence in relatives of British Fanconi Anaemia patients. BMC Cancer 2008: 8: 257.
26. Berwick M, Satagopan JM, Ben-Porat L et al. Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer. Cancer Res 2007: 67: 9591-9596.
27. Rafnar T, Gudbjartsson DF, Sulem P et al. Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet 2011: 43: 1104-1107.
28. Seal S, Thompson D, Renwick A et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006: 38: 1239-1241.
29. Smetsers S, Muter J, Bristow C et al. Heterozygote FANCD2 mutations associated with childhood T Cell ALL and testicular seminoma. Fam Cancer 2012: 11: 661-665.
30. Kalb R, Neveling K, Hoehn H et al. Hypomorphic mutations in the gene encoding a key Fanconi anemia protein, FANCD2, sustain a significant group of FA-D2 patients with severe phenotype. Am J Hum Genet 2007: 80: 895-910.
31. Deans AJ, West SC. DNA interstrand crosslink repair and cancer. Nat Rev Cancer 2011: 11: 467-480.
32. Stone MP, Cho YJ, Huang H et al. Interstrand DNA cross-links induced by alpha, beta-unsaturated aldehydes derived from lipid peroxidation and environmental sources. Acc Chem Res 2008: 41: 793-804.
33. Langevin F, Crossan GP, Rosado IV, Arends MJ, Patel KJ. Fancd2 counteracts the toxic effects of naturally produced aldehydes in mice. Nature 2011: 475: 53-58.
34. Garaycoechea JI, Crossan GP, Langevin F et al. Genotoxic consequences of endogenous aldehydes on mouse haematopoietic stem cell function. Nature 2012: 489: 571-575.
35. Rosado IV, Langevin F, Crossan GP, Takata M, Patel KJ. Formaldehyde catabolism is essential in cells deficient for the Fanconi anemia DNA-repair pathway. Nat Struct Mol Biol 2011: 18: 1432-1434.
36. Hira A, Yabe H, Yoshida K et al. Variant ALDH2 is associated with accelerated progression of bone marrow failure in Japanese Fanconi anemia patients. Blood 2013: 122: 3206-3209.
37. Ciccia A, Ling C, Coulthard R et al. Identification of FAAP24, a Fanconi anemia core complex protein that interacts with FANCM. Mol Cell 2007: 25: 331-343.
38. Leung JW, Wang Y, Fong KW, Huen MS, Li L, Chen J. Fanconi anemia (FA) binding protein FAAP20 stabilizes FA complementation group A (FANCA) and participates in interstrand cross-link repair. Proc Natl Acad Sci U S A 2012: 109: 4491-4496.
39. Zhao Q, Saro D, Sachpatzidis A et al. The MHF complex senses branched DNA by binding a pair of crossover DNA duplexes. Nat Commun 2014: 5: 2987.
40. Fox D 3rd, Yan Z, Ling C et al. The histone-fold complex MHF is remodeled by FANCM to recognize branched DNA and protect genome stability. Cell Res 2014: 24: 560-575.
41. Kottemann MC, Smogorzewska A. Fanconi anaemia and the repair of Watson and Crick DNA crosslinks. Nature 2013: 493: 356-363.
42. Polito D, Cukras S, Wang X et al. The carboxy terminus of FANCE recruits FANCD2 to the FA E3 ligase complex to promote the fanconi anemia DNA repair pathway. J Biol Chem 2014: 289 (10): 7003-7010.
43. Meetei AR, de Winter JP, Medhurst AL et al. A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet 2003: 35: 165-170.
44. Matsuoka S, Ballif BA, Smogorzewska A et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007: 316: 1160-1166.
45. Andreassen PR, D'Andrea AD, Taniguchi T. ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev 2004: 18: 1958-1963.
46. Flynn RL, Zou L. ATR: a master conductor of cellular responses to DNA replication stress. Trends Biochem Sci 2011: 36: 133-140.
47. Shigechi T, Tomida J, Sato K et al. ATR-ATRIP kinase complex triggers activation of the Fanconi anemia DNA repair pathway. Cancer Res 2012: 72: 1149-1156.
48. Ishiai M, Kitao H, Smogorzewska A et al. FANCI phosphorylation functions as a molecular switch to turn on the Fanconi anemia pathway. Nat Struct Mol Biol 2008: 15: 1138-1146.
49. Sims AE, Spiteri E, Sims RJ 3rd et al. FANCI is a second monoubiquitinated member of the Fanconi anemia pathway. Nat Struct Mol Biol 2007: 14: 564-567.
50. Smogorzewska A, Matsuoka S, Vinciguerra P et al. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell 2007: 129: 289-301.
51. Klein Douwel D, Boonen RA, Long DT et al. XPF-ERCC1 acts in unhooking DNA interstrand crosslinks in cooperation with FANCD2 and FANCP/SLX4. Mol Cell 2014: 54: 460-471.
52. Hodskinson MR, Silhan J, Crossan GP et al. Mouse SLX4 is a tumor suppressor that stimulates the activity of the nuclease XPF-ERCC1 in DNA crosslink repair. Mol Cell 2014: 54: 472-484.
53. Duquette ML, Zhu Q, Taylor ER et al. CtIP is required to initiate replication-dependent interstrand crosslink repair. PLoS Genet 2012: 8: e1003050.
54. Murina O, von Aesch C, Karakus U et al. FANCD2 and CtIP cooperate to repair DNA interstrand crosslinks. Cell Rep 2014: 7 (4): 1030-1038.
55. Unno J, Itaya A, Taoka M et al. FANCD2 binds CtIP and regulates DNA-end resection during DNA interstrand crosslink repair. Cell Rep 2014: 7 (4): 1039-1047.
56. Nimonkar AV, Genschel J, Kinoshita E et al. BLM-DNA2-RPA-MRN and EXO1-BLM-RPA-MRN constitute two DNA end resection machineries for human DNA break repair. Genes Dev 2011: 25: 350-362.
57. Ho TV, Scharer OD. Translesion DNA synthesis polymerases in DNA interstrand crosslink repair. Environ Mol Mutagen 2010: 51: 552-566.
58. Nijman SM, Huang TT, Dirac AM et al. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell 2005: 17: 331-339.
59. Du W, Rani R, Sipple J et al. The FA pathway counteracts oxidative stress through selective protection of antioxidant defense gene promoters. Blood 2012: 119: 4142-4151.
60. Li J, Sejas DP, Zhang X et al. TNF-alpha induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells. J Clin Invest 2007: 117: 3283-3295.
61. Zhang X, Li J, Sejas DP, Pang Q. Hypoxia-reoxygenation induces premature senescence in FA bone marrow hematopoietic cells. Blood 2005: 106: 75-85.
62. Koc A, Pronk JC, Alikasifoglu M, Joenje H, Altay C. Variable pathogenicity of exon 43del (FAA) in four Fanconi anaemia patients within a consanguineous family. Br J Haematol 1999: 104: 127-130.
63. De Kerviler E, Guermazi A, Zagdanski AM, Gluckman E, Frija J. The clinical and radiological features of Fanconi's anaemia. Clin Radiol 2000: 55: 340-345.
64. Stivaros SM, Punekar M, Chandler K, Rost I, Schindler D, Meyer S. Pollicisation of the index finger in Fanconi anaemia: appearances and functionality forty years after the intervention. Br J Haematol 2014: 166 (6): 807.
65. Alter BP, Rosenberg PS. VACTERL-H association and fanconi anemia. Mol Syndromol 2013: 4: 87-93.
66. Butturini A, Gale RP, Verlander PC, Adler-Brecher B, Gillio AP, Auerbach AD. Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study. Blood 1994: 84: 1650-1655.
67. Ceccaldi R, Parmar K, Mouly E et al. Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell 2012: 11: 36-49.
68. Rosenberg PS, Alter BP, Ebell W. Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry. Haematologica 2008: 93: 511-517.
69. Scheckenbach K, Morgan M, Filger-Brillinger J et al. Treatment of the bone marrow failure in Fanconi anemia patients with danazol. Blood Cells Mol Dis 2012: 48: 128-131.
70. Rose SR, Kim MO, Korbee L et al. Oxandrolone for the treatment of bone marrow failure in Fanconi anemia. Pediatr Blood Cancer 2014: 61: 11-19.
71. Cioc AM, Wagner JE, MacMillan ML, DeFor T, Hirsch B. Diagnosis of myelodysplastic syndrome among a cohort of 119 patients with fanconi anemia: morphologic and cytogenetic characteristics. Am J Clin Pathol 2010: 133: 92-100.
72. Meyer S, Fergusson WD, Whetton AD et al. Amplification and translocation of 3q26 with overexpression of EVI1 in Fanconi anemia-derived childhood acute myeloid leukemia with biallelic FANCD1/BRCA2 disruption. Genes Chromosomes Cancer 2007: 46: 359-372.
73. Quentin S, Cuccuini W, Ceccaldi R et al. Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. Blood 2011: 117: e161-e170.
74. Tonnies H, Huber S, Kuhl JS, Gerlach A, Ebell W, Neitzel H. Clonal chromosomal aberrations in bone marrow cells of Fanconi anemia patients: gains of the chromosomal segment 3q26q29 as an adverse risk factor. Blood 2003: 101: 3872-3874.
75. MacMillan ML, Wagner JE. Haematopoeitic cell transplantation for Fanconi anaemia - when and how? Br J Haematol 2010: 149: 14-21.
76. Ayas M, Saber W, Davies SM et al. Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia. J Clin Oncol 2013: 31: 1669-1676.
77. Wagner JE, Eapen M, MacMillan ML et al. Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia. Blood 2007: 109: 2256-2262.
78. Peffault de Latour R, Porcher R, Dalle JH et al. Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience. Blood 2013: 122: 4279-4286.
79. Vale MJ, Dinis MJ, Bini-Antunes M, Porto B, Barbot J, Coutinho MB. Audiologic abnormalities of Fanconi anaemia. Acta Otolaryngol 2008: 128: 992-996.
80. Tornquist AL, Martin L, Winiarski J, Fahnehjelm KT. Ocular manifestations and visual functions in patients with Fanconi anaemia. Acta Ophthalmol 2014: 92: 171-178.
81. Rose SR, Myers KC, Rutter MM et al. Endocrine phenotype of children and adults with Fanconi anemia. Pediatr Blood Cancer 2012: 59: 690-696.
82. Giri N, Batista DL, Alter BP, Stratakis CA. Endocrine abnormalities in patients with Fanconi anemia. J Clin Endocrinol Metab 2007: 92: 2624-2631.
83. Sherafat-Kazemzadeh R, Mehta SN, Care MM, Kim MO, Williams DA, Rose SR. Small pituitary size in children with Fanconi anemia. Pediatr Blood Cancer 2007: 49: 166-170.
84. Deepak Amalnath S, Subramanian R, Swaminathan RP, Indumathi N. Incidental detection of Chiari malformation in Fanconi anaemia. Br J Haematol 2012: 158: 154.
85. Rochowski A, Olson SB, Alonzo TA, Gerbing RB, Lange BJ, Alter BP. Patients with Fanconi anemia and AML have different cytogenetic clones than de novo cases of AML. Pediatr Blood Cancer 2012: 59: 922-924.
86. Mehta PA, Ileri T, Harris RE et al. Chemotherapy for myeloid malignancy in children with Fanconi anemia. Pediatr Blood Cancer 2007: 48: 668-672.
87. Reinhard H, Peters I, Gottschling S, Ebell W, Graf N. Squamous cell carcinoma of the tongue in a 13-year-old girl with Fanconi anemia. J Pediatr Hematol Oncol 2007: 29: 488-491.
88. Alter BP, Giri N, Savage SA et al. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol 2010: 150: 179-188.
89. Masserot C, Peffault de Latour R, Rocha V et al. Head and neck squamous cell carcinoma in 13 patients with Fanconi anemia after hematopoietic stem cell transplantation. Cancer 2008: 113: 3315-3322.
90. van Zeeburg HJ, Snijders PJ, Wu T et al. Clinical and molecular characteristics of squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst 2008: 100: 1649-1653.
91. Lyko K, Bonfim C, Benelli EM, Torres-Pereira CC, Amenabar JM. Salivary detection of periodontopathic bacteria in Fanconi's anemia patients. Anaerobe 2013: 24: 32-35.
92. Henrich B, Rumming M, Sczyrba A et al. Mycoplasma salivarium as a dominant coloniser of Fanconi anaemia associated oral carcinoma. PLoS One 2014: 9: e92297.
93. Ichikawa T, Hashimoto J, Yabe M, Kikuchi T, Imai Y. Detection of early esophageal cancer and cervical lymph node metastases by (18)F-FDG PET/CT in a patient with fanconi anemia. Clin Nucl Med 2014: 39: 459-461.
94. Birkeland AC, Auerbach AD, Sanborn E et al. Postoperative clinical radiosens itivity in patients with fanconi anemia and head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2011: 137: 930-934.
95. Spanier G, Pohl F, Giese T, Meier JK, Koelbl O, Reichert TE. Fatal course of tonsillar squamous cell carcinoma associated with Fanconi anaemia: a mini review. J Craniomaxillofac Surg 2012: 40: 510-515.
96. Nabhan SK, Bitencourt MA, Duval M et al. Fertility recovery and pregnancy after allogeneic hematopoietic stem cell transplantation in Fanconi anemia patients. Haematologica 2010: 95: 1783-1787.
97. Mousavi A, Abbasi F, Abadi AG, Hashemi FA. Vulvar squamous cell carcinoma associated with Fanconi's anemia. Int J Hematol 2010: 91: 498-500.
98. Alter BP, Frissora CL, Halperin DS et al. Fanconi's anaemia and pregnancy. Br J Haematol 1991: 77: 410-418.
99. Tolar J, Becker PS, Clapp DW et al. Gene therapy for Fanconi anemia: one step closer to the clinic. Hum Gene Ther 2012: 23: 141-144.
100. Gonzalez-Murillo A, Lozano ML, Alvarez L et al. Development of lentiviral vectors with optimized transcriptional activity for the gene therapy of patients with Fanconi anemia. Hum Gene Ther 2010: 21: 623-630.
101. Rio P, Banos R, Lombardo A et al. Targeted gene therapy and cell reprogramming in Fanconi anemia. EMBO Mol Med 2014: 6: 835-848.
102. de Winter JP, Joenje H. The genetic and molecular basis of Fanconi anemia. Mutat Res 2009: 668: 11-19.
103. Kim Y, Lach FP, Desetty R, Hanenberg H, Auerbach AD, Smogorzewska A. Mutations of the SLX4 gene in Fanconi anemia. Nat Genet 2011: 43: 142-146.